Shire enters into agreement with Sanquin for CINRYZE

The company enters into new agreement with Sanquin

Shire plc (LSE: SHP, NASDAQ: SHPG) announced today it has entered into an agreement with Sanquin Blood Supply, the manufacturer of CINRYZE® (C1 esterase inhibitor [human]), providing Shire access to its manufacturing technology and allowing Shire to source additional manufacturers to meet the growing demand for CINRYZE.

"We wanted the freedom to operate and expand in a way that makes strategic sense for our business," said Flemming Ornskov, M.D., CEO, Shire. "When Shire acquired ViroPharma in January 2014, we inherited an arrangement under which Sanquin was the exclusive manufacturer for CINRYZE. We're pleased that Sanquin was open to expanding our partnership and agreeing to support us as we increase production options for this important therapy."

The specific terms of the agreement are confidential, but involve payments to Sanquin on achievement of certain milestones, including a successful technical transfer to a second source manufacturer. Sanquin will continue to serve as a key partner with Shire to increase global supply of CINRYZE.

Source:

Shire plc

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News-Medical.Net.
Post a new comment
Post
You might also like... ×
Children's Tumor Foundation establishes significant research initiative to combat NF2